Key terms

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ATRC news

Feb 16 8:52am ET AtriCure price target lowered to $42 from $50 at Stifel Feb 16 8:07am ET Stifel Nicolaus Remains a Buy on Atricure (ATRC) Feb 16 7:57am ET Oppenheimer Sticks to Its Hold Rating for Atricure (ATRC) Feb 16 7:34am ET Atricure’s Strong Growth and Positive 2024 Outlook Merit a Buy Rating Feb 16 7:28am ET AtriCure price target raised to $57 from $52 at Canaccord Feb 16 7:27am ET Atricure’s Strong Growth and Market Position Justify Buy Rating and $65 Target Price Feb 16 7:20am ET Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Charles River Labs (CRL) and Shockwave Medical (SWAV) Feb 16 7:18am ET AtriCure price target raised to $58 from $57 at UBS Feb 16 5:55am ET Atricure’s Strong Performance and Growth Potential Merit a Buy Rating Feb 16 2:10am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 15 4:04pm ET AtriCure sees FY24 EPS (82c) to (74c), consensus (69c) Feb 15 4:03pm ET AtriCure reports Q4 EPS (21c), consensus (23c) Jan 22 7:01am ET AtriCure price target raised to $52 from $50 at Canaccord Jan 09 7:47am ET AtriCure’s Growth Trajectory: A Strong Buy Rating with Revenue Surge and Strategic Expansions Jan 08 1:25pm ET Atricure’s Strong Growth and Positive Outlook Justify Buy Rating Jan 08 10:10am ET Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Ascendis Pharma (ASND) and G1 Therapeutics (GTHX) Jan 08 8:11am ET AtriCure sees FY24 revenue $459M-$466M , consensus $454.68M Jan 08 8:09am ET AtriCure sees FY23 EPS (76c)-(74c), consensus (74c) Jan 07 5:50am ET Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT), Apollo Medical Holdings (AMEH) and Atricure (ATRC) Jan 04 8:08am ET AtriCure price target lowered to $44 from $49 at Needham Jan 04 6:40am ET Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and AbbVie (ABBV) Jan 02 9:07am ET Atricure (ATRC) Gets a Buy from BTIG Dec 31 5:06am ET BTIG Keeps Their Buy Rating on Atricure (ATRC) Dec 21 8:40am ET Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Akoya Biosciences (AKYA) Nov 29 12:30am ET Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Ambrx Biopharma (AMAM) Nov 28 2:25pm ET Atricure’s Strong Market Position Justifies Buy Rating Despite New Competition

No recent news articles are available for ATRC

No recent press releases are available for ATRC

ATRC Financials

1-year income & revenue

Key terms

ATRC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ATRC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms